MX347195B - Sistema de administración transdérmica de fármacos y método para usar el mismo. - Google Patents

Sistema de administración transdérmica de fármacos y método para usar el mismo.

Info

Publication number
MX347195B
MX347195B MX2013008543A MX2013008543A MX347195B MX 347195 B MX347195 B MX 347195B MX 2013008543 A MX2013008543 A MX 2013008543A MX 2013008543 A MX2013008543 A MX 2013008543A MX 347195 B MX347195 B MX 347195B
Authority
MX
Mexico
Prior art keywords
delivery system
drug delivery
transdermal drug
steroid
adhesive layer
Prior art date
Application number
MX2013008543A
Other languages
English (en)
Other versions
MX2013008543A (es
Inventor
Ogawa Takahiro
Isowaki Akiharu
Original Assignee
Senju Usa Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senju Usa Inc filed Critical Senju Usa Inc
Publication of MX2013008543A publication Critical patent/MX2013008543A/es
Publication of MX347195B publication Critical patent/MX347195B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061Polyacrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un sistema de administración transdérmica de fármacos que comprende un esteroide como agente activo, en donde el esteroide puede ser propionato de clobetasol, dipropionato de betametasona, amcinonida o etabonato de loteprednol. El sistema de administración transdérmica de fármacos también comprende una capa de adhesivo sensible a la presión y un soporte, en donde el esteroide está presente en la capa de adhesivo sensible a la presión, y en donde la capa de adhesivo sensible a la presión se proporciona en un soporte. El sistema de administración transdérmica de fármacos se puede aplicar sobre el párpado de un paciente en necesidad del mismo, con el fin de tratar una enfermedad del párpado, tal como chalazión, blefaritis o disfunción de las glándulas de Meibomio.
MX2013008543A 2011-06-20 2012-06-19 Sistema de administración transdérmica de fármacos y método para usar el mismo. MX347195B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/164,037 US8900626B2 (en) 2011-06-20 2011-06-20 Transdermal drug delivery system and method of using the same
PCT/US2012/043126 WO2012177626A1 (en) 2011-06-20 2012-06-19 Transdermal drug delivery system and method of using the same

Publications (2)

Publication Number Publication Date
MX2013008543A MX2013008543A (es) 2013-08-12
MX347195B true MX347195B (es) 2017-04-19

Family

ID=47353860

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013008543A MX347195B (es) 2011-06-20 2012-06-19 Sistema de administración transdérmica de fármacos y método para usar el mismo.

Country Status (9)

Country Link
US (1) US8900626B2 (es)
EP (1) EP2720748B1 (es)
JP (2) JP6296977B2 (es)
KR (2) KR20190026963A (es)
CN (1) CN103429295B (es)
CA (1) CA2831095C (es)
ES (1) ES2627514T3 (es)
MX (1) MX347195B (es)
WO (1) WO2012177626A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004064817A1 (ja) * 2003-01-22 2004-08-05 Nichiban Co., Ltd. 眼疾患治療用経皮吸収型製剤、その使用、及び眼疾患治療薬の眼の局所組織への移行方法
US20080114423A1 (en) 2006-05-15 2008-05-15 Grenon Stephen M Apparatus for inner eyelid treatment of meibomian gland dysfunction
US20070060988A1 (en) 2005-07-18 2007-03-15 Grenon Stephen M Melting meibomian gland obstructions
WO2013003594A2 (en) 2011-06-28 2013-01-03 Tearscience, Inc. Methods and systems for treating meibomian gland dysfunction using radio-frequency energy
US7981145B2 (en) 2005-07-18 2011-07-19 Tearscience Inc. Treatment of meibomian glands
US8950405B2 (en) * 2006-05-15 2015-02-10 Tearscience, Inc. Treatment of obstructive disorders of the eye or eyelid
US20090043365A1 (en) 2005-07-18 2009-02-12 Kolis Scientific, Inc. Methods, apparatuses, and systems for reducing intraocular pressure as a means of preventing or treating open-angle glaucoma
US8083787B2 (en) * 2005-07-18 2011-12-27 Tearscience, Inc. Method and apparatus for treating meibomian gland dysfunction
US9314369B2 (en) 2006-05-15 2016-04-19 Tearscience, Inc. System for inner eyelid treatment of meibomian gland dysfunction
US10842670B2 (en) 2012-08-22 2020-11-24 Johnson & Johnson Vision Care, Inc. Apparatuses and methods for diagnosing and/or treating lipid transport deficiency in ocular tear films, and related components and devices
US9211397B2 (en) * 2012-12-19 2015-12-15 Senju Usa, Inc. Patch for treatment of eyelid disease containing clobetasol
US9820954B2 (en) 2015-08-19 2017-11-21 Jenivision Inc. Quantitative peri-orbital application of ophthalmology drugs
US12011388B2 (en) 2016-03-01 2024-06-18 The Hilsinger Company Parent, Llc Therapeutic thermal compress with phase-change material
WO2018003952A1 (ja) * 2016-06-29 2018-01-04 センジュ ユーエスエー、インコーポレイテッド 経皮薬物送達システムおよびその使用方法
USD871598S1 (en) 2016-11-30 2019-12-31 Bruder Healthcare Company, Llc Therapeutic eye mask
USD844795S1 (en) 2016-11-30 2019-04-02 Bruder Healthcare Company, Llc Therapeutic eye mask
AU2018372185B2 (en) * 2017-11-21 2024-05-16 Axerovision, Inc. Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
US11759472B2 (en) 2017-11-21 2023-09-19 Cs Pharmaceuticals Limited Compositions and methods of use for treating aberrant inflammation in peri-ocular secretory glands or at the ocular surface
JP7332602B2 (ja) * 2017-12-28 2023-08-23 センジュ ユーエスエー、インコーポレイテッド 経皮薬物送達システムおよびその使用方法
CA3092966A1 (en) 2018-03-02 2019-09-06 The Schepens Eye Research Institute System and method for treating meibomian gland dysfunction
WO2022010864A1 (en) * 2020-07-06 2022-01-13 Kindeva Drug Delivery L.P. Drug delivery device for delivery of clobetasol propionate
EP4247367A1 (en) 2020-11-23 2023-09-27 Sight Sciences, Inc. Formulations and methods for treating conditions of the eye

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1047519A (en) 1963-06-11 1966-11-02 Glaxo Lab Ltd 17ª‡,21-diesters of 11,17,21-trihydroxy steroid compounds
GB1253831A (en) 1968-01-19 1971-11-17 Glaxo Lab Ltd 9alpha,21-DIHALOPREGNANE COMPOUNDS
ZA744259B (en) 1973-08-17 1975-06-25 American Cyanamid Co Topical steroid
US4666441A (en) 1985-12-17 1987-05-19 Ciba-Geigy Corporation Multicompartmentalized transdermal patches
US4954343A (en) * 1986-03-29 1990-09-04 Nitto Electric Industrial Co., Ltd. Dermal pharmaceutical preparations
EP0334853B1 (en) 1987-10-13 1993-06-09 BODOR, Nicholas S. Soft steroids having anti-inflammatory activity
ZA966579B (en) * 1995-08-04 1998-02-02 Wakamoto Pharma Co Ltd O/W emulsion composition for eye drops.
JP2001009985A (ja) * 1999-07-02 2001-01-16 Hisamitsu Pharmaceut Co Inc 貼付剤用包装袋及び包装貼付剤
WO2001026648A1 (fr) 1999-10-13 2001-04-19 Senju Pharmaceutical Co., Ltd. Preparation d'adhesif a usage ophtalmique pour l'absorption par voie percutanee
US20050058695A1 (en) * 2002-05-30 2005-03-17 Watson Pharmaccuticals, Inc. Norethindrone sustained release formulations and methods associated therewith
WO2004064817A1 (ja) * 2003-01-22 2004-08-05 Nichiban Co., Ltd. 眼疾患治療用経皮吸収型製剤、その使用、及び眼疾患治療薬の眼の局所組織への移行方法
US20050245497A1 (en) * 2004-04-08 2005-11-03 Penfold Philip L Treatment of ophthalmic conditions
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
JP4308255B2 (ja) 2004-05-21 2009-08-05 千寿製薬株式会社 ムスカリン受容体作動薬を含有する眼科用経皮吸収型製剤
CA2597525A1 (en) 2005-02-17 2006-08-24 Senju Pharmaceutical Co., Ltd. Solid ophthalmic drug for external use
WO2006110889A2 (en) * 2005-04-11 2006-10-19 The Board Of Trustees Of The Leland Stanford Junior University Multi-layer structure having a predetermined layer pattern including an agent
US20090143359A1 (en) 2005-07-08 2009-06-04 Akiharu Isowaki Percutaneously Absorptive Ophthalmic Preparation Comprising Epinastine
CN101217937A (zh) 2005-07-08 2008-07-09 千寿制药株式会社 包含奥洛他定的透皮吸收眼科制剂
EP1917964A4 (en) 2005-07-26 2009-11-11 Senju Pharma Co PERCUTANE RESORBIBLE OPHTHALMIC PREPARATION
EP2056809A1 (en) 2006-08-28 2009-05-13 Senju Pharmaceutical Co., Ltd. Ophthalmic percutaneous absorption type preparation
WO2009107477A1 (ja) 2008-02-27 2009-09-03 久光製薬株式会社 貼付製剤
US20090297590A1 (en) 2008-05-30 2009-12-03 Masahiro Yamaji Ketotifen transdermal drug delivery systems and methods for treating ophthalmic disease
CN102066402B (zh) * 2008-06-19 2013-11-06 学校法人近畿大学 肽衍生物以及含有肽衍生物的用于促进泪液分泌的组合物
US10201548B2 (en) 2009-03-06 2019-02-12 Sun Pharma Global Fze Methods for treating ocular inflammatory diseases
TW201039815A (en) * 2009-04-13 2010-11-16 Resolvyx Pharmaceuticals Inc Compositions and methods for the treatment of inflammation
TWI445708B (zh) * 2009-09-02 2014-07-21 Irm Llc 作為tlr活性調節劑之化合物及組合物
LT2493474T (lt) 2009-10-30 2019-10-10 Intratus, Inc. Būdai ir kompozicijos prolonguotam vaistų įvedimui
EP2552724B1 (de) * 2010-03-31 2016-10-19 Kiekert Aktiengesellschaft Stellantrieb für ein kraftfahrzeug sowie verriegelungseinrichtung nebst verfahren
EP2505618A1 (en) * 2011-04-01 2012-10-03 Fábrica Nacional De Moneda Y Timbre Use of electromagnetic wave absorbing markers for the aunthentication of security documents

Also Published As

Publication number Publication date
CA2831095A1 (en) 2012-12-27
KR102107977B1 (ko) 2020-05-07
ES2627514T3 (es) 2017-07-28
EP2720748A4 (en) 2014-11-26
EP2720748A1 (en) 2014-04-23
EP2720748B1 (en) 2017-05-17
JP6296977B2 (ja) 2018-03-20
KR20140019790A (ko) 2014-02-17
KR20190026963A (ko) 2019-03-13
CA2831095C (en) 2015-12-01
CN103429295B (zh) 2017-03-29
JP2014519955A (ja) 2014-08-21
US20120321673A1 (en) 2012-12-20
JP2017048201A (ja) 2017-03-09
MX2013008543A (es) 2013-08-12
US8900626B2 (en) 2014-12-02
CN103429295A (zh) 2013-12-04
WO2012177626A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
MX2013008543A (es) Sistema de administracion transdermica de farmacos y metodo para usar el mismo.
JP2014519955A5 (es)
IN2012DN01225A (es)
MX2016011841A (es) Composiciones topicas de corticosteroides.
MY161021A (en) Controlled release corticosteroid and methods for the treatment of otic disorders
PH12014501351A1 (en) Fluorinated estrogen receptor modulators and uses thereof
SG194155A1 (en) Multilayer thin film drug delivery device and methods of making and using the same
BRPI0713257B8 (pt) sistema terapêutico transdérmico para a aplicação de norelgestromina
WO2011026076A3 (en) Topical formulations comprising a steroid
ATE496617T1 (de) Abgabesystem mit gesteuerter freisetzung zur nasalen anwendung von neurotransmittern
SG10201907588XA (en) Androgen Receptor Modulators And Uses Thereof
MY183873A (en) Transdermal therapeutic system for application of an agent
MX2022008277A (es) Composiciones de gel para administracion transdermica para maximizar las concentraciones de farmaco en el estrato corneo y suero, y metodos de uso de las mismas.
PH12014501078A1 (en) Pharmaceutical compositions and methods of use of 4-pregenen-11�-17-21-triol-3,20-dione derivatives
MX2015008021A (es) Composiciones y metodos para administracion transdermica de hormonas y otros agentes medicos.
IN2014DN09817A (es)
EA201400628A1 (ru) Трансдермальная терапевтическая система для введения фентанила или его аналога
AU2013330679A8 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
BR112012029697A2 (pt) polissacarídeo da semente de tamarindo para uso no tratamento de doenças inflamatórias
PH12014501573A1 (en) Topical pharmaceutical compositions comprising bexarotene and a corticosteroids
WO2012142328A3 (en) Polymer microsphere compositions for localized delivery of therapeutic agents
WO2009076413A3 (en) Methods, devices and compositions for controlled drug delivery to injured myocardium
WO2012111996A3 (ko) 갈란타민 또는 그의 염을 함유하는 경피흡수제제
BR112022012111A2 (pt) Sistema terapêutico transdérmico contendo agomelatina
MX2015010967A (es) Formulaciones transdermicas de laquinimod.

Legal Events

Date Code Title Description
FG Grant or registration